S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Humacyte Stock Forecast, Price & News

-0.05 (-0.95%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
443,583 shs
Average Volume
563,156 shs
Market Capitalization
$537.68 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HUMA News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Humacyte logo

About Humacyte

Alpha Healthcare Acquisition Corp. is a blank check company. It formed for the purpose of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Alpha Healthcare Acquisition Corp. is based in New York.


Humacyte (NASDAQ:HUMA) Hits New 1-Year Low at $5.25
January 20, 2022 |  americanbankingnews.com
Humacyte (NASDAQ:HUMA) Shares Gap Up to $5.41
January 19, 2022 |  americanbankingnews.com
Humacyte (NASDAQ:HUMA) Sets New 1-Year Low at $5.68
January 13, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Cash Flow
$0.11 per share
Book Value
$0.39 per share


Pretax Margin




Free Float
Market Cap
$537.68 million

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

2.04 out of 5 stars

Medical Sector

572nd out of 1,418 stocks

Biological Products, Except Diagnostic Industry

90th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Humacyte (NASDAQ:HUMA) Frequently Asked Questions

Is Humacyte a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Humacyte stock.
View analyst ratings for Humacyte
or view top-rated stocks.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.30. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.27 million.
View Humacyte's earnings history

What price target have analysts set for HUMA?

4 analysts have issued twelve-month price objectives for Humacyte's shares. Their forecasts range from $16.00 to $19.00. On average, they anticipate Humacyte's share price to reach $17.25 in the next year. This suggests a possible upside of 230.5% from the stock's current price.
View analysts' price targets for Humacyte
or view top-rated stocks among Wall Street analysts.

What is Humacyte's stock symbol?

Humacyte trades on the NASDAQ under the ticker symbol "HUMA."

How do I buy shares of Humacyte?

Shares of HUMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Humacyte's stock price today?

One share of HUMA stock can currently be purchased for approximately $5.22.

How much money does Humacyte make?

Humacyte has a market capitalization of $537.68 million.

What is Humacyte's official website?

The official website for Humacyte is www.constellationalpha.com.

Where are Humacyte's headquarters?

How can I contact Humacyte?

Humacyte's mailing address is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 919-313-9633 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.